Richard, Rick, Rich, Rich, Rick, and Rich and Rick and Rich and Rick and all others still with us or now gone. (We sure, at least, in our group have the 3Rs covered.)
Since the AIDS virus has mutated around everything it has been hit with so far, it seems very unlikely that it won't also do that with Androvir. It is almost worth assuming Androvir will also be susceptible to this mutation. But, since Androvir works through the unique technique of kinase inhibition and attacks at a different point, it has a chance to, at least in a cocktail approach, increase the length of time for the mutation to take place. If so, it would be as valuable as the best that is currently out there. Further, since it is coming out under the DHSEA umbrella which limits claims that can be made about it, it is better than advertised while being relatively inexpensive. If this is shown to be true when it goes to market, these virtues will be quickly taken to heart by AIDS patients and groups and other alternative medicine groups.
Its also possible that the AIDS virus operates like a parallel processor and works simultaneously on everything thrown at it in a cocktail and solves all the equations in about 6 months. So that Androvir, though being unique in approach, might not even lengthen the time the virus takes to mutate. But at the least Androvir gives the virus another problem it has to work out. Possibly the cocktail approach will work if enough different problems can be thrown at the virus, 10 or 15 points of attack from totally different approaches (if that many unique points of attack can be found) which may cause overload or a greatly lengthened time to successfully mutate. At this point, Andorvir is, at least, presenting a new problem and point of attack for the AIDS virus to deal with.
The announcement of the official CRADA should also help give further appreciation to the science and technology behind the prln approach.
Larry |
